TrialThe Lancet. Oncology2020

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.

Ian Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.